Calithera Biosciences, Inc. (NASDAQ:CALA) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Friday.

Several other analysts have also recently issued reports on the company. Zacks Investment Research raised Calithera Biosciences from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Thursday, March 30th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $20.00 target price (up previously from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. Leerink Swann reissued an “outperform” rating and issued a $16.00 price objective on shares of Calithera Biosciences in a research report on Monday, April 3rd. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective (up previously from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. Finally, JMP Securities reissued an “outperform” rating and issued a $12.00 price objective on shares of Calithera Biosciences in a research report on Tuesday, March 28th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Calithera Biosciences has an average rating of “Buy” and an average target price of $14.17.

Shares of Calithera Biosciences (CALA) traded down 2.693% during midday trading on Friday, hitting $17.418. The stock had a trading volume of 474,092 shares. The stock’s 50-day moving average is $14.97 and its 200-day moving average is $10.21. Calithera Biosciences has a 12 month low of $2.20 and a 12 month high of $18.10. The stock’s market cap is $614.75 million.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.14. The business had revenue of $4.19 million during the quarter, compared to analysts’ expectations of $1.40 million. Equities analysts anticipate that Calithera Biosciences will post ($0.85) EPS for the current year.

WARNING: “Calithera Biosciences, Inc. (NASDAQ:CALA) Upgraded by BidaskClub to “Buy”” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/07/calithera-biosciences-inc-nasdaqcala-upgraded-by-bidaskclub-to-buy.html.

A number of hedge funds have recently modified their holdings of CALA. FMR LLC boosted its stake in shares of Calithera Biosciences by 6.8% in the fourth quarter. FMR LLC now owns 386,598 shares of the biotechnology company’s stock worth $1,256,000 after buying an additional 24,600 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Calithera Biosciences during the first quarter worth approximately $47,550,000. Tudor Investment Corp ET AL purchased a new stake in shares of Calithera Biosciences during the first quarter worth approximately $1,152,000. Oxford Asset Management purchased a new stake in shares of Calithera Biosciences during the fourth quarter worth approximately $161,000. Finally, Geode Capital Management LLC boosted its stake in shares of Calithera Biosciences by 6.9% in the first quarter. Geode Capital Management LLC now owns 66,250 shares of the biotechnology company’s stock worth $376,000 after buying an additional 4,286 shares in the last quarter. 54.18% of the stock is owned by institutional investors.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.